SCT-200 is under clinical development by SinoCelltech Group and currently in Phase II for Recurrent Head And Neck Cancer Squamous Cell Carcinoma. According to GlobalData, Phase II drugs for Recurrent Head And Neck Cancer Squamous Cell Carcinoma have a 37% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how SCT-200’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
SCT-200 is under development for the treatment of metastatic colorectal cancer, metastatic triple negative breast cancer, esophageal squamous cell carcinoma, squamous non-small cell lung cancer and recurrent head and neck cancer squamous cell carcinoma. It is administered through intravenous route. The drug candidate is a monoclonal antibody. It acts by targeting the epidermal growth factor receptor (EGFR).
It was under development for the treatment of lymphoma, solid tumors including gastric cancer/gastroesophageal junction cancer, hepatocellular carcinoma, pancreatic cancer, bile duct/gallbladder cancer, renal cell carcinoma and ovarian cancer
SinoCelltech Group overview
SinoCelltech Group (SinoCelltech), formerly Beijing Shenzhou Cell Biotechnology Group, is a biopharmaceutical company that discovers, develops monoclonal antibodies, vaccines and recombinant proteins for treatment of cancer, psoriasis and rheumatoid arthritis. SinoCelltech’s pipeline products include SCT200, a human EGFR monoclonal antibody for colorectal cancer, esophageal squamous cell carcinoma, head and neck squamous cell carcinoma and other solid tumors; SCT400, a human-mouse chimeric anti-CD20 monoclonal antibody indicated for non-Hodgkin’s lymphoma; SCT510, a biosimilar of bevacizumab developed for the treatment of non-small cell lung cancer and colorectal cancer; SCT-I10A, a humanized anti-PD-1 IgG4 monoclonal antibody indicated for esophageal squamous cell carcinoma, gastric adenocarcinoma. The company is also evaluating drug candidates targeting for treatment of psoriasis, rheumatoid arthritis and ankylosing spondylitis. SinoCelltech is headquartered in Beijing, China.
For a complete picture of SCT-200’s drug-specific PTSR and LoA scores, buy the report here.